Values
We are very passionate about what we do, and will continue to work hard to ensure that more patients with rare disorders gain access to the correct medical treatment. This results in a healthy and empathic corporate culture that permeates the organisation and helps us to achieve our goals.

Our culture is characterised by high-performing teams that are committed to helping patients with rare disorders and which have a genuinely positive attitude which both motivates and inspires us to do a good job.

Loyalty and reliability are equally fundamental. This applies both within the organisation and in relations with our various partners.

Last but not least, we value open and straightforward communication. We want all our employees to feel comfortable presenting new ideas and suggesting improvements.

Employees
In order to run our business, we need committed and skilled employees – people who take pride in the work they do. Our employees have come to work for Swedish Orphan International because they have a strong desire to make an impact, above all for our patients, but also on the growth and profitability of our company.

One example of our commitment is that we have on several occasions donated drugs to patients who would not otherwise have been able to receive treatment.

Another example is our commitment when it comes to urgent deliveries, round the clock in case of emergencies.

The Group has about 110 employees with an average age of 43. The proportion of women is 63 percent. The majority of our employees have a background in the pharmaceutical industry, often from the big international pharmaceutical companies.

Thanks to our employees, we have extensive expertise in both medical and regulatory matters, as well as business and market-related issues. Our various subsidiaries enable us to ensure local knowledge and experience.

Organisations
Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983.

In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan.

The organisational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, we need an extensive organisation with strong local roots and the ability to see things in a larger perspective. The better and broader our partnerships, the more effectively we can work and the greater the synergies that we can achieve between the various markets.